Want to see OBX full AI Analyst Report?
OBX Stock Chart & Stats
$19.00
<$0.01(0.99%)
At close: 4:00 PM EST
$19.00
<$0.01(0.99%)
Day’s Range― - ―
52-Week Range$3.00 - $49.97
Previous CloseN/A
VolumeN/A
Average Volume (3M)441.35K
Market Cap
$1.05B
Enterprise Value$148.50
Total Cash (Recent Filing)$5.50M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)<0.1
Beta2.65
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding61,772,877
10 Day Avg. Volume978,227
30 Day Avg. Volume441,347
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.33
Price to Sales (P/S)0.00
P/FCF Ratio-0.36
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$42.67Price Target Upside124.56% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt EliminationEliminating debt materially reduces solvency risk, interest burden and refinancing pressure. This gives the company greater financial flexibility while it develops its pipeline, although its modest asset base still limits the overall cushion.
Positive EquityThe return to positive equity represents a meaningful balance-sheet repair from several years of deficits. It improves financial stability and may support continued operations, though the benefit depends on preventing renewed losses and cash depletion.
Narrower Operating LossesThe substantial reduction in operating losses indicates lower ongoing cost intensity than in earlier years. If maintained, this can extend the company’s operating runway and reduce funding needs while clinical or commercial programs develop.
Bears Say
No Operating RevenueThe absence of revenue means the business has not yet demonstrated commercial demand or self-sustaining operations. Future progress therefore depends on successful development, regulatory advancement and eventual monetization of its therapeutic programs.
Persistent Cash BurnAlthough cash burn has declined from earlier periods, continuing negative operating and free cash flow means the company is not funding itself internally. Unless burn falls further or revenue begins, external financing may remain necessary.
Weak Earnings QualityReported profitability appears driven by non-operating items rather than core business performance. This limits the usefulness of headline earnings as a measure of durable progress and leaves operating losses and cash generation as the key risks.
Obsidian Therapeutics News
OBX FAQ
What was Obsidian Therapeutics’s price range in the past 12 months?
Obsidian Therapeutics lowest stock price was $3.00 and its highest was $49.97 in the past 12 months.
What is Obsidian Therapeutics’s market cap?
Obsidian Therapeutics’s market cap is $1.05B.
When is Obsidian Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Obsidian Therapeutics’s earnings last quarter?
Currently, no data Available
Is Obsidian Therapeutics overvalued?
According to Wall Street analysts Obsidian Therapeutics’s price is currently Undervalued.
Does Obsidian Therapeutics pay dividends?
Obsidian Therapeutics does not currently pay dividends.
What is Obsidian Therapeutics’s EPS estimate?
Obsidian Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Obsidian Therapeutics have?
Obsidian Therapeutics has 61,772,877 shares outstanding.
What happened to Obsidian Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Obsidian Therapeutics?
Currently, no hedge funds are holding shares in OBX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Obsidian Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$42.67 (124.56% Upside)
$42.67 (124.56% Upside)
Blogger Sentiment
Neutral
OBX Sentiment 100%
Sector Average 63%
Sector Average 63%
Hedge Fund Trend
Decreased
By 8.4K Shares
Last Quarter.
Last Quarter.
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
304.76%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
750.56%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Obsidian Therapeutics
A clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor-infiltrating lymphocyte (TIL) cell therapies for the treatment of patients with solid tumors. Its proprietary cytoDRiVE® technology is designed to precisely regulate the timing and level of protein function by using FDA-approved small-molecule drugs.
OBX Stock 12 Month Forecast
Average Price Target
$42.67
▲(124.56% Upside)
Technical Analysis
Ownership Overview
98.80% Insiders
<0.01% Mutual Funds
― Other Institutional Investors
1.17% Public Companies and
Individual Investors